Literature DB >> 27956931

Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report.

Filipe Manuel Dos Reis Simões da Silva1, Peter Mike Burgos Pêgo1, Maria Cristina Henriques Vendrell1, Maria João de Azevedo Batalha Ferreira Dos Santos Farias1, Ângela Cátia Ribeiro Timóteo2, Maria Cristina Martins da Costa2, Isabel Maria Monteiro Barbosa Moreira Cravo3, Fernando Manuel Ribeiro Gomes4.   

Abstract

Posterior reversible encephalopathy syndrome is an increasingly recognised clinico-radiological entity, associated with several medical conditions (such as systemic arterial hypertension) and characterised by seizures, altered mental status, headaches, and visual symptoms. Magnetic resonance imaging is a key component in this diagnosis, with hyperintense foci in T2-weighted images, corresponding to vasogenic oedema. The pathophysiology is not fully understood but probably involves loss of auto-regulation of cerebral vasculature or endothelial dysfunction or both. A 56-year-old male, suffering from a gastro-intestinal stromal tumour with hepatic metastasis resistant to imatinib, on therapy with sunitinib, came to the Emergency Department because of headaches, hallucinations, and loss of vision. There was no previous history of high blood pressure. A hypertensive crisis was diagnosed; ophthalmological examination on admission showed no light perception bilaterally. Brain imaging displayed bilateral parieto-occipital and frontal vasogenic oedema, consistent with the clinical diagnosis of posterior reversible encephalopathy syndrome. After treatment of hypertension and suspension of sunitinib, the patient recovered from his symptoms. Control imaging showed no oedema. Angiogenesis inhibitors, such as sunitinib and bevacizumab, can cause hypertension, one of the many medical conditions associated with the posterior reversible encephalopathy syndrome. This syndrome should be considered in cases of acute visual loss, particularly in view of its reversible nature when diagnosed and treated promptly.

Entities:  

Keywords:  bevacizumab; cortical blindness; posterior reversible encephalopathy syndrome; sunitinib; vasogenic oedema

Year:  2011        PMID: 27956931      PMCID: PMC5145282          DOI: 10.3109/01658107.2010.539763

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  29 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed.

Authors:  V L Stott; M A Hurrell; T J Anderson
Journal:  Intern Med J       Date:  2005-02       Impact factor: 2.048

Review 2.  Posterior reversible encephalopathy syndrome in intensive care medicine.

Authors:  Giuseppe Servillo; Francesca Bifulco; Edoardo De Robertis; Ornella Piazza; Pasquale Striano; Fabio Tortora; Salvatore Striano; Rosalba Tufano
Journal:  Intensive Care Med       Date:  2006-11-21       Impact factor: 17.440

3.  Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

Authors:  E Kapiteijn; A Brand; J Kroep; H Gelderblom
Journal:  Ann Oncol       Date:  2007-10       Impact factor: 32.976

4.  Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.

Authors:  Ghassan El Maalouf; Emmanuel Mitry; Alexis Lacout; Astrid Lièvre; Philippe Rougier
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

Review 5.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

6.  Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.

Authors:  Erkan Dogan; Sercan Aksoy; Cagatay Arslan; Didem S Dede; Kadri Altundag
Journal:  Med Oncol       Date:  2010-12       Impact factor: 3.064

7.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Authors:  Jeffrey A Allen; Ashish Adlakha; Peter R Bergethon
Journal:  Arch Neurol       Date:  2006-10

8.  Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.

Authors:  Carolyn Fein Levy; Khine Zin Oo; Fernando Fireman; Louisdon Pierre; Marita A Bania; Swayamprabha Sadanandan; Darrell J Yamashiro; Julia L Glade Bender
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

9.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

10.  Recurrent posterior reversible encephalopathy syndrome in mitochondrial disorder.

Authors:  Josef Finsterer; Claudia Stöllberger; Eva Ostermann; Günther Zuntner; Johannes Huber; Robert Tscherney
Journal:  Blood Press       Date:  2009       Impact factor: 2.835

View more
  1 in total

1.  Ocular complications with the use of radium-223: a case series.

Authors:  Julie R Bloom; Alexandra G Castillejos; Brianna Jones; Nimesh Patel; Barry S Rosenstein; Richard G Stock
Journal:  Radiat Oncol       Date:  2022-05-17       Impact factor: 4.309

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.